Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

Schedule of Share-based Compensation Expense

The table below summarizes the impact of recording stock-based compensation expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss during the three months ended March 31, 2020 and 2019:



	Three Months Ended March 31,
	2020		2019
Cost of goods sold	$	164	$	227
Operating expenses:
Research and development	181		332
Clinical and regulatory affairs	166		186
Marketing and sales	299		709
General and administrative	923		907
Total operating expenses	1,569		2,134
Total	$	1,733	$	2,361